

ST98032.ST25.txt
SEQUENCE LISTING

<110> Aventis Pharma S.A.

<120> Use Of Specific Hybrid Promoters For Controlling Tissue Expression

<130> ST98032

<150> US 60/123298

<151> 1999-04-04

<150> FR/98/12000

<151> 1998-09-25

<160> 10

<170> PatentIn version 3.0

<210> 1

<211> 23

<212> DNA

<213> Artificial

<220>

<223> Artificial Sequence

<220>

<221> nucleotide

<222> (1)...(23)

<400> 1

gatggtcctt acttatgctg cta

23

<210> 2

<211> 23

<212> DNA

<213> Artificial

<220>

<223> artificial sequence

<220>

<221> nucleotide

<222> (1)...(23)

ST98032.ST25.txt

<400> 2
cttccatcat accaaactac ata
23

<210> 3
<211> 32
<212> DNA
<213> Artificial

<220>
<223> artificial sequence

<220>
<221> nucleotide
<222> (1)..(32)

<400> 3
ctgctaaatt gctcgaggac aaatttagaca aa
32

<210> 4
<211> 33
<212> DNA
<213> Artificial
•
<220>
<223> artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(33)

<400> 4
ccctgacaaa gcttggctgg gctgctccac tgg
33

<210> 5
<211> 30
<212> DNA
<213> Artificial

<220>
<223> artificial sequence

<220>

ST98032.ST25.txt

<221> oligonucleotide
<222> (1)..(30)

<400> 5
atcgacgcgt gccccgttaca taacttacgg
30

<210> 6
<211> 38
<212> DNA
<213> Artificial

<220>
<223> artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(38)

<400> 6
atcgacgcgt ccgctcgagc gtcaatgggg cggagttg
38

<210> 7
<211> 36
<212> DNA
<213> Artificial

<220>
<223> artificial sequence

<220>
<221> oligonucleotide
<222> (1)..(36)

<400> 7
ccaggctgca ctcgagacta gttcccacca actcga
36

<210> 8
<211> 36
<212> DNA
<213> Artificial

<220>

ST98032.ST25.txt

<223> artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(36)

<400> 8
tcgttgaag cttggaagga gagtagcttc ggtgtc
36

<210> 9
<211> 30
<212> DNA
<213> Artificial

<220>

<223> artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(30)

<400> 9
cccgttacat aacttacggt aaatggcccg
30

<210> 10
<211> 30
<212> DNA
<213> Artificial

<220>

<223> artificial sequence

<220>

<221> oligonucleotide

<222> (1)..(30)

<400> 10
gggacgcgct tctacaaggc gctggccgaa
30